These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 32988414)
21. A Case of Isolated Adrenocorticotropic Hormone Deficiency Caused by Pembrolizumab. Bekki T; Takakura Y; Kochi M; Konemori Y; Oki K; Yoneda M; Egi H; Ohdan H Case Rep Oncol; 2020; 13(1):200-206. PubMed ID: 32308578 [TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab-Induced Diabetes Mellitus Presenting as Diabetic Ketoacidosis in a Patient With Metastatic Colonic Adenocarcinoma. Kichloo A; Albosta MS; McMahon S; Movsesian K; Wani F; Jamal SM; Aljadah M; Singh J J Investig Med High Impact Case Rep; 2020; 8():2324709620951339. PubMed ID: 32830561 [TBL] [Abstract][Full Text] [Related]
24. A Case of Acute Exacerbation of Chronic Adrenal Insufficiency Due to Ipilimumab Treatment for Advanced Melanoma. Sakaguchi C; Yano S; Ashida K; Wada N; Ohe K; Nagata H; Matsuda Y; Sakamoto S; Sakamoto R; Ohnaka K; Uchi H; Furue M; Nomura M; Ogawa Y Am J Case Rep; 2019 Jan; 20():106-110. PubMed ID: 30679413 [TBL] [Abstract][Full Text] [Related]
25. Isolated ACTH deficiency following immunization with the BNT162b2 SARS-CoV-2 vaccine: a case report. Morita S; Tsuji T; Kishimoto S; Uraki S; Takeshima K; Iwakura H; Furuta H; Nishi M; Inaba H; Matsuoka TA BMC Endocr Disord; 2022 Jul; 22(1):185. PubMed ID: 35854260 [TBL] [Abstract][Full Text] [Related]
26. Isolated autoimmune adrenocorticotropic hormone deficiency: From a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors. Percik R; Shlomai G; Tirosh A; Tirosh A; Leibowitz-Amit R; Eshet Y; Greenberg G; Merlinsky A; Barhod E; Steinberg-Silman Y; Sella T Autoimmun Rev; 2020 Feb; 19(2):102454. PubMed ID: 31838158 [TBL] [Abstract][Full Text] [Related]
27. Diabetic ketoacidosis induced by a single dose of pembrolizumab. Maamari J; Yeung SJ; Chaftari PS Am J Emerg Med; 2019 Feb; 37(2):376.e1-376.e2. PubMed ID: 30361152 [TBL] [Abstract][Full Text] [Related]
28. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report. Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422 [TBL] [Abstract][Full Text] [Related]
29. Diabetic Ketoacidosis: An Adverse Reaction to Immunotherapy. Keerty D; Das M; Hallanger-Johnson J; Haynes E Cureus; 2020 Sep; 12(9):e10632. PubMed ID: 33123445 [TBL] [Abstract][Full Text] [Related]
30. Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. Aleksova J; Lau PK; Soldatos G; McArthur G BMJ Case Rep; 2016 Nov; 2016():. PubMed ID: 27881588 [TBL] [Abstract][Full Text] [Related]
31. A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma. Wu L; Li B Diabetes Metab Syndr Obes; 2021; 14():753-757. PubMed ID: 33628041 [TBL] [Abstract][Full Text] [Related]
32. Metachronous immune-related adverse events involving type 1 diabetes and isolated adrenocorticotropic hormone deficiency associated with pembrolizumab monotherapy for metastatic head and neck cancer: a case report. Iijima H; Sakai A; Ebisumoto K; Yamauchi M; Teramura T; Yamazaki A; Inagi T; Okami K J Med Case Rep; 2023 Sep; 17(1):387. PubMed ID: 37697390 [TBL] [Abstract][Full Text] [Related]
33. Critical Care Admission of an HIV Patient with Diabetic Ketoacidosis Secondary to Pembrolizumab. Cuenca JA; Laserna A; Reyes MP; Nates JL; Botz GH Case Rep Crit Care; 2020; 2020():8671530. PubMed ID: 32274219 [TBL] [Abstract][Full Text] [Related]
34. Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism. Patel S; Chin V; Greenfield JR Endocrinol Diabetes Metab Case Rep; 2019 Dec; 2019():. PubMed ID: 31829972 [TBL] [Abstract][Full Text] [Related]
35. Isolated adrenocorticotropic hormone deficiency development during chemotherapy for gastric cancer: a case report. Kinoshita J; Higashino S; Fushida S; Oyama K; Watanabe T; Okamoto K; Nakamura K; Takamura H; Ninomiya I; Kitagawa H; Fujimura T; Ohta T J Med Case Rep; 2014 Mar; 8():90. PubMed ID: 24597969 [TBL] [Abstract][Full Text] [Related]
36. New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer. Cunha C; Silva E; Vieira AC; Saraiva C; Duarte S Endocrinol Diabetes Metab Case Rep; 2022 Feb; 2022():. PubMed ID: 35140188 [TBL] [Abstract][Full Text] [Related]
37. Fulminant diabetes due to immune checkpoint inhibitors in the emergency department. Peyrony O; Ellouze S; Fontaine JP; Mohamadou I; Zafrani L Am J Emerg Med; 2020 Feb; 38(2):408.e3-408.e4. PubMed ID: 31759780 [TBL] [Abstract][Full Text] [Related]
38. Isolated Adrenocorticotropic Hormone (ACTH) Deficiency as an Immune-Related Adverse Event Following Combination Immune Checkpoint Inhibitor Therapy. Matsushiro M; Shibue K; Osawa K; Hamasaki A Cureus; 2024 Jun; 16(6):e62863. PubMed ID: 39040756 [TBL] [Abstract][Full Text] [Related]
39. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report. Li S; Zhang Y; Sun Z; Hu J; Fang C Medicine (Baltimore); 2018 Nov; 97(45):e12907. PubMed ID: 30407284 [TBL] [Abstract][Full Text] [Related]
40. Pituitary-adrenal axis dysfunction induced by tislelizumab immunotherapy for non-small cell lung cancer: a case series and literature review. Wang J; Lan H; Mao X; Chen Y BMC Pulm Med; 2024 Jul; 24(1):327. PubMed ID: 38977996 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]